Prescient Therapeutics Ltd

ASX:PTX ISIN:AU000000PTX3

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. 
 
           

Voir en d'autres langues

Nouvelles

###

135,415 COMPANY PROFILE VIEWS

  • This Page Viewed: (7 derniers jours: 19) (Last 30 Days: 56) (Since Published: 10365) 

Company Data

    Fax
  • (03) 9853 5134 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.virax.com.au/

More News Results

  • 2025/01/22: Final Director's Interest Notice*
  • 2025/01/22: Notification regarding unquoted securities - PTX*
  • 2025/01/13: Notification of cessation of securities - PTX*
  • 2024/12/23: US FDA allows PTX-100 Ph2 trial*
  • 2024/12/17: Appointment of Chief Executive Officer*
  • 2024/12/11: Change of Director's Interest Notice*
  • 2024/12/11: Notification regarding unquoted securities - PTX*
  • 2024/12/04: Change of Director's Interest Notices x4*
  • 2024/12/04: Notification of cessation of securities - PTX*
  • 2024/11/14: Results of Annual General Meeting*
*refer to company website